Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Influence of APOE genotype on cerebrovascular cell pathobiology in AD, and the contribution of microglia inflammation

Award Number: R03AG073829
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/15/2021
PERIOD OF PERFORMANCE END DATE: 06/30/2024

Group Awards By:

View Award Description

Influence of APOE genotype on cerebrovascular cell pathobiology in AD, and the contribution of microglia inflammation - Alzheimer’s disease (AD) is an age-related neurodegenerative disorder and the predominant type of dementia, marked by brain deposits of amyloid plaques and neurofibrillary tangles. An often overlooked pathognomonic lesion of AD is cerebrovascular degeneration. Abnormalities in cerebral blood flow are a preclinical feature of AD that manifest many years before symptom onset. Vascular lesions are also routinely observed in AD brains at different stages of the disease. Disruptions to cerebrovascular integrity can impact on neuronal function, however, the main driver of these vascular changes in AD remains elusive. The Apolipoprotein E4 (APOE4) allele is one of the strongest risk factors for AD, and has been shown to significantly impact on cerebrovascular health, precipitating deficits in cerebral perfusion, vascular lesions and damage to the blood brain barrier. Yet, more longitudinal studies are needed to better understand how APOE4 can significantly impact on cerebrovascular cell pathobiology in the sequelae of AD pathogenesis. In the brain, APOE is produced primarily by glial cells, and in AD, disease associated microglia (DAM’s) are known to upregulate APOE expression, which mediates the transcriptional proinflammatory phenotype of these cells. DAM’s have been shown to drive the outcome and pace of APOE-mediated neuronal dysfunction, but very little is currently known about the role they play in contributing to cerebrovascular changes in AD, particularly, how this is influenced by APOE genotype. To address these questions, we plan to use mouse models expressing human forms of APOE and A to clarify the role played by APOE4 as a molecular driver of cerebrovascular cell pathobiology, and how this is influenced by DAM’s. We will explore longitudinal cerebrovascular cell pathobiology at timepoints representing pre, peri and post onset of A pathology using histopathological and ultrastructural analyses. We will also confirm the contribution of DAMs on cerebrovascular pathobiology by utilizing microglia ablation techniques to depopulate DAMs and also repopulate newborn microglia in our mouse models. To date, no studies have characterized the molecular transcripts of reactive cerebrovascular cell phenotypes in these combined models. Thus, we will conclude our studies using single cell gene analyses of cerebrovascular cells (endothelial cells, pericytes, smooth muscle cells) to reveal their unique and detailed time-course of responses. We will confirm differentially expressed genes in autopsied cerebrovascular tissue from staged AD cases to validate the translational relevance of our findings and map against mouse AD-related pathogenic timelines. From this proposal, we aim to identify novel (cerebrovascular) cell specific targets in the early stages of disease through which the APOE4 allele confers neurological risk. Our future goal will be to explore the functional effects of these targets, and to provide new therapeutic opportunities to promote cerebrovascular health and restoration of cognitive function in AD.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	THE ROSKAMP INSTITUTE, INC.	2040 WHITFIELD AVE	SARASOTA	FL	34243	MANATEE	USA	Aging Research	000	2	7/16/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2022	ROSKAMP INSTITUTE INC, THE	2040 WHITFIELD AVE	SARASOTA	FL	34243	MANATEE	USA	Aging Research	000	2	7/21/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $161,991 )
2022	2022	ROSKAMP INSTITUTE INC, THE	2040 WHITFIELD AVE	SARASOTA	FL	34243	MANATEE	USA	Aging Research	000	2	7/15/2022	NON-COMPETING CONTINUATION	$161,991
														Subtotal = $161,991

Issue Date FY: 2021 ( Subtotal = $161,991 )
2021	2021	ROSKAMP INSTITUTE INC, THE	2040 WHITFIELD AVE	SARASOTA	FL	34243	MANATEE	USA	Aging Research	000	1	8/11/2021	NEW	$161,991
														Subtotal = $161,991

Grand Total All Awards = $323,982

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Influence of APOE genotype on cerebrovascular cell pathobiology in AD, and the contribution of microglia inflammation

Award Number: R03AG073829

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/15/2021

PERIOD OF PERFORMANCE END DATE: 06/30/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer